CELG-RI Company Profile and Key Details

The stock is currently trading near its 52-week high $0.11 and $0.11. With a market capitalization of about $220.20 million, Bristol-Myers Squibb Company Ce is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.47). Key stats such as the average daily volume over the past year has been around 27.59 thousand shares, volume is running light vs its 52-week average. Headquartered in Princeton, NJ, Bristol-Myers Squibb Company Ce operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Christopher S. Boerner, the company employs approximately 34,100 people and listed since November 21, 2019. Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution.

Bristol-Myers Squibb Company Ce trades at a P/E ratio of 0.03, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.01 suggesting the stock is closer to book value. The P/FCF stands at 0.02, also above market averages.

CELG-RI has shown sold momentum, gaining 17.37% over the past week and 81.82% over the past quarter, though year-to-date performance is up 81.82%. Average 10-day trading volume of 37.80 thousand shares is significantly above the 3-month average of 18.30 thousand, indicating heightened recent market interest.

Bristol-Myers Squibb Company Ce earnings surprise history is a mixed track record. The quarter that ended July 30, 2026, missed forecasts by 27.5%. The prior quarter beat by 11.27%. Over the last six quarters, Apple has recorded several small beats. These include -18.79% in April 24, 2025.

Our AI price prediction model suggests that Bristol-Myers Squibb Company Ce stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -16.51%, with price expected at $0.09 by November 24, 2023, within a range of $0.08 to $0.09

Bristol-Myers Squibb Company Ce (NYSE:CELG-RI) shares are up 81.82% year-to-date Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Bristol-Myers Squibb Company Ce trading at a premium to the broader market with a P/E of 0.03.

Bristol-Myers Squibb Company Ce last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $464.63. This means the shares are trading below this model’s fair value.